The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NSKE8     diazanium9-[(2R,4S,5R)-4- (hydroxy-oxido...

Synonyms: M3808_SIGMA, MRS2179, MRS 2179, CTK8G1195, HMS3262G14, ...
This record was replaced with 5311303.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid

  • The selective P2Y1 receptor antagonist 2'-deoxy-N6-methyl-adenosine-3',5'-diphosphate (MRS2179) and the G(i) protein inhibitor pertussis toxin blocked Ca2+ increase [1].
  • P2Y1-deficient mice and mice treated with the P2Y1 antagonist MRS2179 displayed significantly less arterial thrombosis than their respective controls [2].
  • Venous thrombosis was slightly but significantly inhibited in MRS2179-treated rats [2].

High impact information on [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid

  • Neurosphere cell proliferation was attenuated after application of the P2Y(1)-receptor antagonist MRS2179 and in neurospheres from P2Y(1)-receptor knockout mice [3].
  • The effects of ATP and ADP on cell migration and proliferation were prevented by the P2Y(1) antagonist MRS2179 [4].
  • Antagonists of the Gq-coupled P2Y1 ADP receptor, A3P5P (500 microM) and MRS2179 (100 microM), have no effect [5].
  • These data, in conjunction with results obtained by using the P2 receptor antagonists TNP-ATP, PPADS and MRS2179 indicate that the current response to alpha,beta-meATP is due to P2X3 receptor activation, while the ATP-induced rise in [Ca2+]i is evoked by P2Y1 and P2Y4 receptor activation [6].
  • MRS2179, a selective P2Y1 purinergic receptor antagonist, blocked both the slow EPSP and mimicry of the EPSP by exogenously applied ATP [7].

Biological context of [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid

  • A synergistic effect regarding inhibition of ADP-induced platelet activation (10 microM) was obtained with different combinations of AR-C69931MX and MRS2179 [8].
  • The phosphorylation was reduced both by removal of the extracellular Ca2+ and partially or almost completely by MRS2179 or AR-C69931MX, specific antagonists of the P2Y1 and P2Y12 receptors, respectively [9].
  • MRS2179, a selective P2Y1 purinergic receptor antagonist, suppressed the ATP-evoked responses in a concentration-dependent manner with an IC50 of 0.9+/-0.1 microM [10].
  • Ap(5)X and Ap(6)X induced dose-dependent vasodilation that was due to P2Y(1) receptor activation, as evidenced by use of the selective P2Y(1) receptor antagonist 2'-deoxy-N(6)-methyl-adenosine 3',5'-diphosphate diammonium (MRS2179) [11].
  • Finally, intravenous injection of MRS2179 resulted in inhibition of rat platelet aggregation in response to ADP and prolonged the bleeding time, in rats or mice, as compared to controls [12].

Anatomical context of [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid

  • In contrast, no inhibition of rP2Y(13) receptor was induced by the selective P2Y(1) receptor antagonist MRS2179. rP2Y(13) receptor showed highest expression levels in spleen, followed by liver and brain (with particularly high levels in cortex and striatum as reported in man), suggesting important roles in the nervous and immune systems [13].
  • Application of 2meSATP elicited MRS2179-sensitive time- and voltage-dependent inward currents in the interneurons, which depolarized the cell to firing threshold [14].

Associations of [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid with other chemical compounds


Gene context of [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid

  • 9. TCIPA induced by alphavbeta3/MT1-MMP cells was also reduced by inhibiting the generation and actions of ADP with apyrase (250 microg ml(-1)) and 2-methylthio-AMP (2-MeSAMP) (30 microm), but not N(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate (MRS2179) (30 microm) [17].
  • Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist [2].
  • Blocking of the P2Y1 receptor by MRS2179 additionally increased this ADP response [9].

Analytical, diagnostic and therapeutic context of [(2R,3S,5R)-5-(6-methylaminopurin-9-yl)-3-phosphonooxy-oxolan-2-yl]methoxyphosphonic acid

  • Based on the above findings, on pharmacological inhibition by the antagonists oxATP and MRS2179, and on the absence of alpha,betameATP-induced inward current in whole-cell recording, P2X(7) and P2Y(1) were identified as the main ionotropic and metabotropic P2 receptors active in OPs [4].
  • In contrast, the height was reduced to 5.4 +/- 2.2 and 3.3 +/- 1.3 microm, respectively (p < 0.01, n = 8), when the blood used in the second 6-min perfusion contained a P2Y1 (MRS2179) or P2Y12 (AR-C69931MX) inhibitor [18].


  1. Activation of P2Y1 receptor triggers two calcium signaling pathways in bone marrow erythroblasts. Paredes-Gamero, E.J., Craveiro, R.B., Pesquero, J.B., França, J.P., Oshiro, M.E., Ferreira, A.T. Eur. J. Pharmacol. (2006) [Pubmed]
  2. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. Lenain, N., Freund, M., Léon, C., Cazenave, J.P., Gachet, C. J. Thromb. Haemost. (2003) [Pubmed]
  3. Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation. Mishra, S.K., Braun, N., Shukla, V., Füllgrabe, M., Schomerus, C., Korf, H.W., Gachet, C., Ikehara, Y., Sévigny, J., Robson, S.C., Zimmermann, H. Development (2006) [Pubmed]
  4. Metabotropic P2 receptor activation regulates oligodendrocyte progenitor migration and development. Agresti, C., Meomartini, M.E., Amadio, S., Ambrosini, E., Serafini, B., Franchini, L., Volonté, C., Aloisi, F., Visentin, S. Glia (2005) [Pubmed]
  5. ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets. Fälker, K., Lange, D., Presek, P. Thromb. Haemost. (2004) [Pubmed]
  6. Characterization of P2X3, P2Y1 and P2Y4 receptors in cultured HEK293-hP2X3 cells and their inhibition by ethanol and trichloroethanol. Fischer, W., Wirkner, K., Weber, M., Eberts, C., Köles, L., Reinhardt, R., Franke, H., Allgaier, C., Gillen, C., Illes, P. J. Neurochem. (2003) [Pubmed]
  7. Slow excitatory synaptic transmission mediated by P2Y1 receptors in the guinea-pig enteric nervous system. Hu, H.Z., Gao, N., Zhu, M.X., Liu, S., Ren, J., Gao, C., Xia, Y., Wood, J.D. J. Physiol. (Lond.) (2003) [Pubmed]
  8. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Nylander, S., Mattsson, C., Ramström, S., Lindahl, T.L. Br. J. Pharmacol. (2004) [Pubmed]
  9. Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells. Czajkowski, R., Banachewicz, W., Ilnytska, O., Drobot, L.B., Baranska, J. Br. J. Pharmacol. (2004) [Pubmed]
  10. Neurogenic secretion mediated by the purinergic P2Y1 receptor in guinea-pig small intestine. Fang, X., Hu, H.Z., Gao, N., Liu, S., Wang, G.D., Wang, X.Y., Xia, Y., Wood, J.D. Eur. J. Pharmacol. (2006) [Pubmed]
  11. Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. van der Giet, M., Schmidt, S., Tölle, M., Jankowski, J., Schlüter, H., Zidek, W., Tepel, M. Eur. J. Pharmacol. (2002) [Pubmed]
  12. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Baurand, A., Raboisson, P., Freund, M., Léon, C., Cazenave, J.P., Bourguignon, J.J., Gachet, C. Eur. J. Pharmacol. (2001) [Pubmed]
  13. Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor. Fumagalli, M., Trincavelli, L., Lecca, D., Martini, C., Ciana, P., Abbracchio, M.P. Biochem. Pharmacol. (2004) [Pubmed]
  14. Direct excitation of inhibitory interneurons by extracellular ATP mediated by P2Y1 receptors in the hippocampal slice. Kawamura, M., Gachet, C., Inoue, K., Kato, F. J. Neurosci. (2004) [Pubmed]
  15. Purinergic P2Y6 receptors induce Ca2+ and CFTR dependent Cl- secretion in mouse trachea. Schreiber, R., Kunzelmann, K. Cell. Physiol. Biochem. (2005) [Pubmed]
  16. Endothelium-dependent, MRS2179-independent actions of uridine 5'-triphosphate in guinea pig aorta. Kaiser, R.A., Buxton, I.L. Proc. West. Pharmacol. Soc. (2001) [Pubmed]
  17. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Alonso-Escolano, D., Strongin, A.Y., Chung, A.W., Deryugina, E.I., Radomski, M.W. Br. J. Pharmacol. (2004) [Pubmed]
  18. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. Goto, S., Tamura, N., Ishida, H., Ruggeri, Z.M. J. Am. Coll. Cardiol. (2006) [Pubmed]
WikiGenes - Universities